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Stmamary 
5-Lipoxygenase activation  of human blood polymorphonudear  cells  (PMN)  from asthmatic 
patients (asthmatics) was studied to investigate whether differences may exist with healthy sub- 
jects  (controls).  The  respective  cell  capacities  to  produce  lipoxins  (LXs),  leukotrienes,  and 
5(S),15(S)-dihydroxyeicosatetraenoic  acid [5(S),15(S)-diHETE]  were compared under in vitro 
stimulation by ionophore A23187, with or without exogenous 15(S)-hydoxyeicosatetraenoic 
acid [15(S)-HETE]. Eicosanoids were analyzed by elution with an isocratic reverse-phase high 
performance liquid chromatography system, and their profiles, detected by simultaneous moni- 
toring at 302, 280, and 246 nm, were evaluated on the basis of chromatographic behavior: UV 
spectral  characteristics  and coelution  with synthetic standards.  In the  presence  of exogenous 
15(S)-HETE, human PMN were able to produce LXs and 5(S),15(S)-diHETE. Moreover, the 
total  amount  of LXs biosynthesized by PMN  from asthmatics  was twofold higher than that 
biosynthesized by PMN from controls. In the absence of exogenous 15(S)-HETE, PMN from 
asthmatics  were  able  to  produce  5(S),15(S)-diHETE,  and  LXs  from  endogenous  sources, 
whereas in the same experimental conditions, no detectable amounts of  these compounds were 
released  by PMN  from controls.  The  levels  of 5(S),15(S)-diHETE,  and LXs biosynthesized 
from endogenous arachidonic acid were highly correlated. Two different LX patterns were ob- 
served involving two possible metabolic pathways: (a) via the intermediate  5,6-epoxytetraene 
alone for LXs generation from exogenous 15(S)-HETE; and (b) via 5,6- and/or 14,15-epoxytet- 
raenes leading to the formation of an enzyme-bound delocalized carbocation for LXs genera- 
tion from endogenous arachidonate,  respectively.  The enhanced 5-lipoxygenase activation of 
blood  PMN  from asthmatics  and  the  metabolism  of exogenous  15(S)-HETE  may reflect  a 
priming induced by various mediators released from environmental cells, and could be consid- 
ered as a model of transcellular signalization between PMN and endothelial cells. 
T 
he  generation  of arachidonic  acid  metabolites  by li- 
poxygenase-catalyzed reacdous is associated with acti- 
vation  of a  wide  range  of human  cell  types  that  are  in- 
volved in both physiologic and pathophysiologic events (1). 
Human  blood  PMN,  which  are  able  to  biosynthesize 
eicosanoids from the 5-1ipoxygenase (5-LO) 1 pathway (2), 
are likely to be involved in inflammatory disorders such as 
asthma and rheumatoid arthritis (3-6). Moreover, previous 
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~Abbrev/at/ans used m ~  pa~: AM, alveolar  macrophagerg  5-HETE, 5(S)- 
hydroxyeicosatetraenoic acid; 12-HETE,  12(S)-hydroxyeicosate~aenoic 
aci& 15(S)-HETE, 15~q~ydroxyeic~no*c acid; 5(S),ISCS)-~HETE, 
5(S),15(S)-dihydroxyeicosa~ic  acid; 15(S)-HPETE, 15(S)--hydro- 
peroxyeicosatetraenoic acid; LT, leukotnene; LTA4, 5(S)-5,6-oxido--I  1,14- 
cis-7,9-traas~eicosatelraenoic a~-id; LTB~, 5(S),i2(R)--dihydroxy--6,14-c/s- 
8,10-trans--eicosatetraenoic acid; LTC  4,  5(S),6(R)-5-hydroxy--6-(S-glu- 
tathionyl)-7,9-trans-I  1,14-as--eicosatetraenoic acid; LX, lipoxines; LXA4, 
(5S, 6R,  15S)-tfihydroxy-7,9,13-trans-ll-cis-eicosatetraenoic acid; 6S- 
LXA  4, (5S, 6S,  15S)-trihydroxy-7,9,13-trans-  11 --ds--eicosateWaenoic  acid; 
11-trans-LX/~, (5S, 61~, lSS~-trJhydroxy-7,9,11,13-~rans-eicosatewaenoic 
acid; 6S-ll-trans-LXA4, (5S, 6S,  15S)-trihydroxy-7,9,11,13-trans-eico- 
satetraenoic acid; 7-ds-ll-trans-LXA  4,  (5S, 6R,  15S)-trihydroxy-9,ll, 
13-trans-7-ds--eicosatetraenoic acid; LXB4, (5S, 14R,  15S)-trihydroxy- 
6,10,12-trans-8--ds--eicosatetraenoic acid; 8--ttans-LXB4, (5S, 141~ 15S)- 
trihydroxy-6,8,10,12-trans-eicosatetraenoic acid; 14S-8-trans-LXB4, (5S, 
t4S, 15S)-trilaydroxy-6,8,10,12-trans--eicosatewaenoic  acid; RP-HPLC, re- 
verse~phase high performance liquid chromatography. 
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tients with inflammatory diseases is enhanced as compared 
to  5-LO  activity  of cells  from  healthy  subjects  (controls) 
(7-10). This high level of 5-LO activity may occur as a re- 
sult  of specific cellular activation due  to cooperation with 
surrounding blood cells.  It is now well established that tran- 
scellular metabolism resulting from the cell-cell interactions 
lead to lipoxin (LXs) biosynthesis as a result of the interac- 
tion  between  several  lipoxygenases  (11,  12).  Moreover, 
Serhan demonstrated the importance of LX involvement in 
respiratory disease, suggesting their chalone-like role in the 
inflammatory response and their impact in cell regulation (13). 
Considering that human lung tissues displayed high lev- 
els  of 15-LO  activity  (14)  and  that  LXs  were  found  in 
bronchoalveolar lavage from patients with severe pulmonary 
diseases  (15),  we designed, in a previous study, a model of 
cellular  cooperation  between  alveolar macrophages  (AM) 
and bronchial epithelial  cells  (16).  We have  demonstrated 
that AM from asthmatic patients  (asthmatics),  incubated in 
the  presence  of exogenous  15(S)-hydroxyeicosatetraenoic 
acid  (15(S)-HETE),  produced  in  vitro  twofold  higher  li- 
poxin amounts  than AM from healthy subjects  (controls). 
Simultaneously, Lew et al.  demonstrated that in cytokine- 
primed  human  AM,  15-LO  activity was  induced  so  that 
the cells produced lipoxins from exogenously added arachi- 
donic  acid  or  LTA  4  (5(S)-5,6-oxido-11,14-cis-7,9-trans- 
eicosatetraenoic  acid)  (17).  More  recently,  we  demon- 
strated that LX generation by human PMN was correlated 
with the severity of inflammatory diseases  (18,  19).  Nano- 
gram  (picomole)  levels  of hpoxins  are  generated  after  (a) 
human whole-blood stimulation  (20) without the addition 
of exogenous substrate;  (b) receptor-mediated activation of 
both  PMN  and  platelets  during  coincubation  conditions 
(21); and (c) ionophore stimulation of PMN alone after ex- 
posure to exogenous  15(S)-HETE  (22).  According to this 
background, we decided to investigate whether the generation 
of LXs and 5,15-dihydroxyeicosatetraenoic acid [5 (S), 15 (S)- 
diHETE]  is related  to the  severity of asthma.  Since PMN 
are able to respond to various stimuli through the synthesis 
of arachidonic  acid-derived  mediators  involved  in  acute 
and  chronic inflammatory processes,  the  aim  of this  study 
was  to  determine  the  mechanisms  that  induce  5(S),15(S)- 
diHETE  and  LXs  generation,  and  to  investigate  whether 
these mediators may be considered as potential biomarkers 
of asthma more specific than leukotrienes  (LTs). 
PMN activation via the 5-LO pathway was estimated by 
analysis  of the  structure  and level  of the  eicosanoids  pro- 
duced after cell stimulation by Ca  2+ ionophore  (A 23187) 
alone or together with 15(S)-HETE. The ionophore of di- 
valent cation is not cell type specific, but it is a useful tool 
for the generation of individual eicosanoid in amounts that 
facilitate  their  isolation  and  structural  determination  by 
physical methods. 
Materials  and Methods 
Reagents.  Culture materials, nutritive  medium, and FCS came 
from Flow Laboratories (Courbevoie, France). All solvents were of 
HPLC grade and obtained from Farmitalia Carlo Erba (Milan, It- 
aly).  LTC4  (5(S),6(R)-5-hydroxy-6-(S-glutathionyl)-7,9-trans- 
11,14-cis-eicosatetraenoic  acid),  LTB4  (5 (S), 12(R)-dihydroxy- 
6,14-cis-8,10-trans-eicosatetraenoic  acid), 20 OH-LTB4, 5S-, 12S-, 
and 15(S)-HETE, 5(S),15(S)-diHETE,  LXA  4 ((5S, 6R,  15S)-tri- 
hydroxy-7,9,13-trans-11-cis-eicosatetraenoic  acid),  and  LXI34 
((5S,  14R,  15S)-trihydroxy-6,10,12-trans-8-cis-eicosatetraenoic 
acid) were from Cayman Chemical Company (Ann Arbor, MI). 
6S-LXA  4 ((5S, 6S,  15S)-trihydroxy-7,9,13-trans-lI-cis-eicosatet- 
raenoic  acid)  was  from Cascade  (Reading,  UK).  8-trans-LXB 4 
((5S,  14R,  15S)-trihydroxy-6,8,10,12-trans-eicosatetraenoic  acid), 
14S-8-trans LXB 4 ((5S,  14S, 15S)-trihydroxy-6,8,10,12-trans-eico- 
satetraenoic  acid),  ll-trans  LXA  4  ((5S, 6R,  15S)-trihydroxy- 
7,9,11,13-trans-eicosatetraenoic  acid), 6S-11-trans-LXA  4 ((5S, 6S, 
15S)-trihydroxy-7,9,11,13-trans-eicosatetraenoic  acid),  and  MK 
886  were generous gifts from Dr.  C.B.  Pickett  and  Dr.  A.W. 
Ford-Hutchinson (Merck Frosst, Montreal, Canada). 
Subjects.  The study included 7 healthy subjects (controls)  and 
38  asthmatic  patients  (asthmatics).  None  of the  subjects  were 
smokers  and they were free  of medication  that might interfere 
with the study design. Theophylline and [3 agonists were stopped 
1 wk before the study;  nonsteroidal antiinflammatory drugs  and 
corticosteroids  had  been  discontinued  for at  least  1  mo.  The 
seven controls were without any history of allergy or respiratory 
diseases. The clinical  characteristic  of the 38  asthmatics  are  de- 
scribed  in Table 1. Asthma was defined according to the Ameri- 
can Thoracic Society as previously described  in detail  (23).  All 
patients  had a reversible  airways obstruction characterized  by an 
increase of at least 12% in the FEVI value and an absolute value of 
200 ml after inhalation of 200 Ixg of salbutamol  (24). The study 
was performed after informed consent, and it fulfilled the criteria 
of the Ethics Commitee of the University of Montpellier. 
Preparation of PMN.  The cells were isolated and purified from 
heparinized (20 U/ml) venous blood (50 ml) by centrifugation of 
samples at 400 g for 20 rain at 20~  over discontinuous Percoll 
gradient  (25). The PMN suspension  in Percoll  was added to an 
equal volume of saline and then centrifuged at 400 g for 10 rain. 
The pellet  was resuspended into 20 ml of a solution of NH4C1/ 
Tris/K2CO 3 (0.130/0.01/0.016  M) (pH 7.4) to lyse contaminat- 
ing erythrocytes.  After centrifugation,  6.10v-8.10 v PMN were re- 
covered. Cells were then resuspended into PBS (pH 7.4) contain- 
ing CaCI2 and MgC12 (final concentration =  2 ￿  10 _3 and 0.5  ￿ 
10 .3 M, respectively).  PMN purity was evaluated  after cytocen- 
trifugation and May Griinwald staining, and it was always >95%. 
There was no statistical differences  in the number of eosinophils 
in controls and asthmatics, as reported in previous works (26). Vi- 
ability  determined by the trypan blue exclusion test was >90%. 
PMN were adjusted to 107 ceUs/ml, and the cell suspensions were 
prewarmed at 37~  for 5 min before ionophore stimulation. 
Table  1.  Characteristics  of Healthy Subjects and Asthmatic Patients 
Controls  Asthmatics 
Number  7  38 
Age (yr)  35.4 +  3.2  37.2 _+ 6.3 
Gender  4 male/3 female  24 male/14 female 
FEV~ (% predicted)  100 +  1.6  83.8  +  7.7 
FEV  l is forced expiratory volume in 1 s expressed as the percentage of 
the predicted value. Data are expressed as mean values +  SEM. 
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conected in polypropylene tubes containing acid-citrate-dextrose 
anticoagulant as previously described  (27) and centrifuged at 200 
g for 15 rain. The platelet-rich plasma was further centrifuged at 
650 g for an additional 20 rain. Cell pellet was washed in glucose 
buffer (Tris-HCl 15 raM, NaC1 134 raM, EDTA 1 raM, glucose 
5 mM, pH 7.4),  recentrifuged, and then adjusted  to 1.109 cells/ 
ml into Hepes-tyrode buffer to prevent aggregation.  Aliquots of 
0.50,  0.25,  0.10,  and 0.01 ml were adjusted  to 1 ml adding PBS 
with Ca  2+ and Mg  2+, and prewarmed at 37~  for 2 rnin before 
ionophore stimulation ofplatelets alone. 
Platelet-PMNCoincubations.  Platelet  suspension  aliquots  of 
0.50, 0.25, 0.10, and 0.01 ml were added to 107 PMN (platelets/ 
PMN ratios 50, 25,  10, and 1, respectively).  The mixtures were 
centrifuged and the pellets  were resuspended into 1 ml of PBS 
containing  Ca ++ and Mg  ++, and incubated at 37~  for 2 rain be- 
fore stimulation with ionophore alone. 
Stimulation Procedures.  A  23187  (final concentration =  5  X 
10 -6 M) was added to the cell suspension with or without 15(S)- 
HETE (final concentration =  3  ￿  10 -6 M) in ethanol (minimal 
concentration 0.1%),  and incubation was  continued for 5 rain. 
When 15(S)-HETE was added,  it was preincubated for 2 rain at 
room  temperature.  PMN  from  controls  were  incubated both 
with and without 15(S)-HETE. PMN from asthmatics were in- 
cubated without  15(S)-HETE  (n  =  25)  or in the  presence of 
15(S)-HETE (n =  13). Several experiments were carried out on 
cells prewarmed at 37~  in the presence of MK 886 (2.5 ￿  10 -7 
M). Simultaneous experiments with 15(S)-hydroperoxyeicosatet- 
raenoic acid (15(S)-HPETE) were carried out on cells from sev- 
eral  study patients, in the  same  conditions. Incubations of the 
same  amounts of 15(S)-HETE and  15(S)-HPETE were carried 
out in PBS alone to test for the possibihty ofautoxidation. At the 
end of stimulation, the supernatant was separated  from the cells 
by centrifugation at 2,000 g, and were added to 1 ml of ice-cold 
methanol to stop the reaction. The samples were stored at -20~ 
for further analysis of extracellular metabolites.  The cell pellet was 
resuspended in 1 ml PBS,  to which  1 ml of ice-cold methanol 
was added. The samples were stored at -70~  for further analysis 
of intracellular metabolites.  After one night at  -70~  the cell 
suspensions were centrifuged and the supernatant was stored  for 
the  study of cell-associated  free  HETE.  For  covalently linked 
HETE analysis, the pellet was treated with 0.1  rnl NaOH 2 N 
and 0.4 ml MeOH at 37~  for 1 h. Then the solution was neu- 
tralized by addition of 0.1 ml of acetic acid 2 N, and the volume 
was adjusted to 1 ml with additional MeOH. After centrifugation, 
the samples were directly injected onto the analytical column. 
Metabolite Identification and Quantification.  The  stored  samples 
were directly investigated by reverse-phase  HPLC  (RP-HPLC) 
analysis, as previously described  (16). 
(a)  Dihydroxy-  and  trihydroxyeicosatetraenoic acid  analysis: 
P,.P-HPLC was carried out on a Lichrospher 100 RP-18 column 
(150  ￿  3.9 ram, 5-~m particles;  Merck, Darmstadt,  Germany). 
LXs, LTs,  and 5(S),15(S)-diHETE were eluted with methanol/ 
water/acetic  acid  (65:35:0.1,  vol/vol/vol, pH  5.6)  containing 
0.5% EDTA as the mobile phase; they were detected by simulta- 
neously monitoring the  following wave lengths:  302,  270,  and 
246 nm, corresponding to ~  .... of conjugated tetraenes,  trienes, 
and dienes, respectively. 
(b)  Monohydroxy-eicosatetraenoic acid  analysis:  R.P-HPLC 
was performed on a Nucleosil C18 column (250 ￿  3.9 ram, 5-lxm 
particles)  and  eluted  with  methanol/water/acetic  acid  (78:32: 
0.01, vol/vol/vol) with the UV detector set at 237 nm. 
(c) Detection and quantification.  Arachidonic  acid  metabolites 
were identified using cochromatography with synthetic standards 
and UV spectroscopy  in stop-flow mode. They were quantified by 
external standard method, on the basis of molecular extinction co- 
efficients of 55,000,  35,000 and 28,000 for conjugated tetraenes, 
trienes, and dienes, respectively. The sensitivity threshold was 0.2 
ng at 302 rtrn and 0.5-1 ng at the other wave lengths. 
Statistical Analysis.  The  results  presented  as  nanograms per 
107 cells were expressed  as mean +  SEM.  Statistical differences 
were determined using the Mann-Whitney U  test for unpaired 
samples (experiments  on PMN from controls,  n =  7; experiments 
on PMN from asthmatics incubated without 15(S)-HETE, n  = 
25; experiments on PMN from asthmatics incubated with 15(S)- 
HETE, n =  13). Significance level was set at P <0.05. Correla- 
tions were evaluated using the Spearman rank correlation. 
Results 
5-LO activity in human PMN was investigated via LXs 
and  5(S),15(S)-diHETE  biosynthesis under conditions of 
stimulation by A  23187 alone or together with exogenous 
15(S)-HETE.  Experiments with  15(S)-HPETE were  car- 
tied  out simultaneously on PMN  from several asthmatics 
(the  results  were  identical to  those  obtained with  15(S)- 
HETE).  Some experiments were  carried out in the pres- 
ence of A  23187 alone on platelet-PMN mixtures and on 
platelet suspensions to compare the results with those ob- 
tained with PMN alone. 
Two series of experiments were carried out: (a) without 
addition of exogenous substrate for PMN from 25 asthmat- 
ics; and (b) with exogenous added 15(S)-HETE for the cells 
from  13  asthmatics.  The same  experiments were  simulta- 
neously performed on PMN from seven controls. 
Eicosanoid Biosynthesis from Endogenous  Sources (PMN  from 
7 Controls and 25 Asthmatics).  Stimulation of human PMN 
by A23187 alone generated products containing conjugated 
diene detected at 237  nm, and conjugated triene detected 
at 280 nm. Fig.  1 A  reports the analysis results at 280 nm 
for 20-OH LTB  4,  A6-trans  LTB4 isomers generated from 
nonenzymatic LTA  4  opening and  LTB  4,  with  retention 
times of 6.80,  20.50,  20.22,  and 24.70  rain, respectively. 
All the  metabolites were  released mainly into the  culture 
medium, but 20% of them remained associated in the cell 
pellet.  No  detectable amounts of LTC  4 were  observed in 
controls or asthmatics.  Simultaneous detection at 246  nm 
usually showed the same eicosanoid pattern with character- 
istic  equal peak  areas for  the  two  A6-trans-LTB 4 isomers 
since the  molecular extinction coefficients were  identical 
for all LTB  4 metabolites containing conjugated triene chro- 
mophore.  The  asthmatics  cell analysis of the  supernatant 
and the  cell pellet detected  a  new peak  with  a  retention 
time of 22.40 rain (Fig.  1 B).  This product coeluted with 
authentic  5(S),15(S)-diHETE  and  showed  the  same  UV 
spectrum as the reference standard, with a maximum at 246 
nm and a shoulder at 235 nm, which is characteristic of a 
double-conjugated diene (28). 
Simultaneous detection at 302 nm, which did not usually 
reveal any metabolites in these analysis conditions, showed 
for  the  asthmatics'  PMN  several  peaks  with  UV  spectra 
1635  Chavis et al. r 
r 
A  LTB4 
6-trans-LTB, 
B 
eq 
0  '  1"  0  '  '  '  "-  '  ; 0  '  '  20  20 
5,15-diHETE 
246nm 
/L 
|  |  ￿9  ￿9 
220  240  260 
I  D 
TIME  min 
Figure  1.  RP-HPLC  profiles  of dihy- 
droxy  arachidonic  acid metabolites  gener- 
ated by human PMN.  107 cells/m1 were in- 
cubated for 5 rain at 37~  with A 23187  (5 
p.M)  with  and  without  15(S)-HETE  (3 
p.M)  for  controls cells,  with  15(S)-HETE 
only for one group of asthmatics cells  (n = 
t3),  and without  exogenous precursor for 
another group of asthmatics cells  (n =  25). 
Sample  aliquots  were  injected directly  on 
RP-HPLC,  and  chromatography  was  car- 
ried  out  with  eluting  solvent  methanol/ 
water/acetic  acid  (65:35:0.1  vol/vol/vol) 
adjusted to pH 5.6, at a flow rate of 0.5 nil/ 
min for 15 min and 1 ml/min from 15 to 65 
min.  Peaks were identified by comparison 
of their elution time with those of synthetic 
standards  and  by  their  UV  spectra.  The 
same  metabolite  pattern  was  obtained  for 
the cells from asthmatics or controls stimu- 
lated  in  the presence of 15(S)-HETE  and 
for  the  cells  from  asthmatics  stimulated 
without  15(S)-HETE.  (A)  Recording  at 
280 nm corresponding to conjugated triene 
hn~. (B) Recording at 246 nm correspond- 
ing to h~  of double-conjugated diene 5(S)-15(S)-diHETE.  Inset,  stop-flow UV spectrum of 5(S),15(S)-diHETE  (h,~ 246 nm with shoulder at 237 
nm); arrows, the elution positions of authentic standards. Chromatograms A and B are derived from one representative experiment (cells from the same 
donor), and the experiment was repeated several times with similar results. 
giving a  triplet  of absorption bands  at 288,  302,  and 316 
nm, which is characteristic of the conjugated tetraene sys- 
tem of the LX structure  (Fig.  2, insert).  Fig.  2  displays ex- 
pansion of the LX region monitored at 302 nm. The me- 
tabolite  stereochemistries were  assigned  to  the  respective 
peaks by several successive chromatographic superimposi- 
tions with synthetic standards according to the method de- 
scribed in a previous work (16).  The peak with a retention 
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Figure 2.  RP-HPLC profiles of trihydroxy arachidonic acid metabolites generated by human PMN. 107 cells/rnl were incubated for 5 min at 37~ 
with A 23187  (5 I~M) with and without 15(S)-HETE. Expansion of the lkP-HPLC chromatograms were recorded at 302 nm corresponding to conju- 
gated tetraene hm~, under the conditions described in Fig, 1. (A) Focus on the LX region related to the PMN from asthmatics (n =  13) and from controls 
(n =  7) incubated with exogenous 15(S)-HETE. (B) Focus on the region related to the cells from asthmatics (n =  25) incubated without exogenous pre- 
cursor. Inset,  stop-flow characteristic UV spectrum of the conjugated tetraene system of the LX structure (k~o~ 302 nm with shoulders at 288 and 316 
nm). As reported for Fig.  1, chromatograms A and B are derived from one representative experiment, and the experiments were repeated several times 
with similar results. 
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at 9.30  min coeluted with  14S-8-trans-LXB4  isomers that 
were not resolved in this mobile phase. The peak at 12.60 
min coeluted with natural LXA  4, the peak at 11.40 rain co- 
eluted with 11-trans-LXA  4 and 6S-11-trans-LXA  4 isomers, 
and the peak at 14.80 min with 6S-LXA  4. 
Detection at 237 nm showed the presence of 5-HETE, 
as usually described for PMN, but failed to point out any de- 
tectable amounts of 15(S)-HETE, 12-HETE, or 12-hydroxy- 
heptadecawienoic acid, even after cell pellet hydrolysis. 
Fig. 3  reports the amounts of all the metabolites gener- 
ated in vitro by the two cell populations after A23187 stim- 
ulation.  PMN  from  asthmatics  released  significantly into 
their culture medium higher levels of20-OH-LTB4, LTB4, 
and LTB  4 isomers than PMN from controls: 203.5  +-  9.1 
vs 139.4 -+  12.8 (P <0.0008), 173.1  +- 9.1 vs 153.7 +  12.8 
(P <0.0008), and 144.8  -- 6.3 vs 113.2  -+ 6.8 ng/107 cells 
(P <0.0045),  respectively. Besides the normally generated 
LTs, PMN from asthmatics were able to generate marked 
amounts  of  5(S),15(S)-diHETE  (135.4  +-  14.2  rig/107 
cells), as well as LXs  (6.1  +  1.0 ng/10  v cells), whereas no 
detectable  amounts  of  these  metabolites  were  found  in 
PMN from controls. Moreover, the metabolite levels were 
highly correlated, as shown in Fig. 4. Among the asthmatics 
cells this study shows evidence of two cell types: "high re- 
sponders" (n =  13), which cells biosynthesized 5,15-di-HETE 
levels  >150  ng  and  "mild  responders"  (n  =  12),  with 
correlation coefficients  r  =  0.803  (P  <0.003)  and 0.942 
(P <0.0001) respectively. 
PMN from asthmatics incubated in the presence ofA23187 
were able to biosynthesize from their endogenous arachi- 
donic acid pool LTB4, 20-OH-LTB4, LTB4 isomers, dihy- 
droxy derivatives containing conjugated dienes identified as 
5(S),15(S)-diHETE, and trihydroxy derivatives containing 
conjugated tetraene identified as LXB4-trans-isomers,  LXA  4- 
trans-isomers, and 6S-LXA  4 and the two natural LXA  4 and 
LXB  4,  with  relationships  between  dihydroxy  acid  levels 
and total LX amounts. 
Eicosanoid Biosynthesis  from Exogenous 15(S)-HETE (PMN 
from  7 Controls and 13 Asthmatics).  Exposure  of PMN  to 
A  23187  in the  presence of 15(S)-HETE resulted in the 
generation of products containing conjugated diene, triene, 
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Figure  3.  Di- and trihydroxy products generated from endogenous 
sources by human PMN. The cells from controls and asthmatics were 
stimulated by A 23187 (5 p,M) at 37~  for 5 man. The total amounts of 
biosynthesized metabolites  were identified by tkP-HPLC, as outlined in 
Fig. 1. They were quantified  by external  standard method (comparison  of 
the peak area to standard curves obtained in the same conditions  of analy- 
sis on the basis of molecular  extinction coefficients  of 55,000, 35,000, and 
28,000 for conjugated tetraenes, trienes, and dienes respectively). These 
results represent  the total amounts of the metabolites  released into the cul- 
tnre medium and of the metabolites  associated to the cells. Results pre- 
sented as nanograms  per 107 cells were expressed as mean -+ SEM from 
the number of subjects in each population. Filled  bars, asthmatics (n -- 25); 
hashed bars, controls (n = 7). Eicosanoid  levels  were higher in PMN from 
asthmatics with significant  differences (except for LTB4): *P <0.0043, 
"'P <0.0008,  ***P <0,0001 (Mann-Whitney U  test). No  detectable 
amount  of LXs  and  5(S),15(S)-diHETE were found  in  PMN  from 
controls. 
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Figure  4.  Correlations between LXs  and 5(S),15(S)-diHETE levels 
generated by PMN from asthmatics (n =  25). The cells were stimulated 
by A 23187 (5 ￿  10  -6 M for 5 min at 37~  without exogenous 15(S)- 
HETE, in the conditions  as described in Fig. 1 legend. Data are expressed 
as nanograms  per 10  ~  cells. The two cell populations  were determined by 
the high 5(S),15(S)-diHETE  levels (upper  panel, 5(S),15(S)-diHETE  levels 
>150 ng/107 cells, n =  13) and by the lower 5,5-diHETE levels (lower 
panel, n =  12). r = 0.803 with P <0.003 and r = 0.942 with P <0.0001, 
respectively (Spearman rank correlation). and tetraene as previously reported (22, 29). They were de- 
tected simultaneously at 246, 280, and 302 nm on the same 
sample injection. The profiles obtained at 246 nm with ex- 
ogenous added  15(S)-HETE  did  not  differ from that  ob- 
tained  without  15(S)-HETE  (same  pattern  as  reported  in 
Fig.1  B), but the profile recorded at 280 nm differed by the 
absence  of  A6-trans-LTB4  and  by  the  twofold  lower 
amounts of LTs. Fig. 2 A, which gives the profile of conju- 
gated tetraene-containing products, also showed two marked 
differences with that obtained for biosynthesis from endog- 
enous  sources  (Fig.  2  B):  (a)  the  low  amounts  of natural 
LXB4, undetectable in our experimental conditions of anal- 
ysis and;  (b)  the  generation  of a  product with  a  retention 
time  at  11.40  rain,  which  was  identified  as  the  7-cis-11- 
trans-LXA  4,  according  to  published  data  (30).  When  the 
cells  were incubated  in  the presence  of MK 886,  none of 
the metabolites were detected. 
PMN  from  asthmatics  and  controls,  stimulated  by  A 
23187  in  the presence  of 15(S)-HETE,  were  thus  able  to 
synthesize LTB  4 and its metabolites, and to transform exog- 
enously  added  15(S)-HETE  into  dihydroxy  derivatives, 
5(S),15(S)-diHETE,  and  into  trihydroxy  derivatives  con- 
taining conjugated tetraene,  all-trans-LXB 4 isomers, cis- and 
trans-LXA  4 isomers, LXA  4, and 6S-LXA  4. 
In conclusion,  we  observed that  the  eicosanoid pattern 
obtained  from  experiments  with  exogenously added  pre- 
cursor  differed  from  the  profile  obtained  without  exoge- 
nous 15(S)-HETE. 
Biosynthesis of LXs  and  5(S), 15(S)-diHETE from  Exoge- 
nously Added 15(S)-HETE in Asthma.  Since  15(S)-HETE 
and related compounds have been described as human leu- 
kocyte 5-LO inhibitors (31),  15(S)-HETE was added at 3  p~M 
(final  concentration)  to  107 PMN/1  ml PBS: this  concen- 
tration may not be cytolytic and provided the best ratio of  LXs 
vs  LT  biosynthesis.  Dose-response  experiments  showed 
that  exogenous  15(S)-HETE  >6  p,M  failed  to  enhance 
LXs and 5(S),15(S)-diHETE  levels in human PMN, while 
LTB4 synthesis was strongly decreased;  <3  ~M,  generated 
LX levels  remained  within  the  detection  threshold  range 
(data not shown). 
Fig.  5  shows the results  concerning all  eicosanoids pro- 
duced  by  107  PMN  in  the  presence  of exogenous  15(S)- 
HETE.  Comparing Figs.  3  and 5, partial  inhibition  of the 
LT  biosynthesis  occured  for both  the  controls  and  asth- 
matics  cells,  with  a  highly  significant  twofold  decrease 
(P <0.0001).  20-OH-LTB4 and LTB4 levels in PMN from 
asthmatics were higher (80.9  -+  10.2 and 52.2  -4-  10.3 ng/ 
107  cells)  than  those  in PMN  from controls  (50.1  _+  26.5 
and 30.1  -+  17.7), but the differences were not significant. 
It is  noteworthy  that  A6-trans-LTB 4 formation was  com- 
pletely  inhibited  for both  asthmatics  and  controls.  More- 
over,  15(S)-HETE transformation into 5(S),15(S)-diHETE 
by PMN  from asthmatics  was nearly  twofold higher  than 
by PMN from controls: 93.5  -+ 3.1% vs 59.0  -+  7.6% for- 
mation from the total added 15(S)-HETE, with very signif- 
icant differences  (P <0.0005).  Similarly,  LXs, which were 
biosynthesized in the same level range as LTs (Fig, 6), were 
twofold  more  important  in  asthmatics  than  in  controls: 
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Figure 5.  Di- and trihydroxy products generated by A 23187-stimu- 
lated PMN in the presence of 15(S)-HETE. PMN were stimulated A 
23187 (5 p~M) for 5 min at 37~  with 15(S)-HETE (3 heM) in the condi- 
tions described in Fig. 1 legend. The amounts of metabolites were deter- 
mined by RP-HPLC analysis by external standard method, as outlined in 
Fig. 3. As reported in the Fig. 3 legend, they represented the whole-cell 
production. Results presented as nanograms per 107 cells for LTs and LXs 
are reported on the left vertical axis. Results presented as the percentages 
of 5(S),15(S)-diHETE formation from  the  initial added 15(S)-HETE 
amounts are reported on the right vertical axis. The results are expressed 
as mean + SEM for the number of  subjects in each population. Filled  bars, 
asthmatics (n  =  13); hashed bars, controls (n  ~  7). LT production was 
lower  than in  the  cells incubated without  15(S)-HETE (see Fig. 3). 
Eicosanoid levels were higher in asthmatics' PMN than in controls' cells, 
with significant differences for  the  LX pathway only: ***P <0.0005 
(Mann-Whimey U test). 
56.8  -+ 4.0 ng vs 23.0  -+ 2.5 ng/107 cells,  with highly sig- 
nificant differences (P <0.0001). 
The amounts and distribution  of trihydroxy compounds 
obtained  for  the  cells  from  controls  and  asthmatics  were 
detailed in Fig. 6. Total LXs levels were determined as the 
sum of the four groups of products resolved by HPLC elu- 
tion:  two  LXB  4 isomers,  two  all-trans-LXA 4 isomers  plus 
7-cis-ll-trans-LXA4,  LXA  4,  and  6S-LXA  4 (Fig.  2  A),  and 
were biosynthesized in the 3:3:3:1 ratio that is independent 
of the pathology. The level of every group of isomers was 
significantly higher  in  cells  from asthmatics  than  in  those 
from controls: LXB  4 isomers  (16.4  -+  1.4 ng vs 8.1  ---  1.3 
ng, P  <0.0001), LXA  4 isomers (14.9  -  1.9 ng vs 5.6  •  0.6 
ng,  P  <0.0005),  LXA  4  (17.3  •  0.8  ng vs  6.5  _+  0.8  ng, 
P  <0.0001),  and  6S-LXA  4  (6.1  .T-  +  0.8  ng  vs  2.4  -  0.5, 
P  <0.005).  Thus, PMN from asthmatics were able to syn- 
thesize greater levels of total LXs than PMN from controls, 
but  16.3%  of these  metabolites  remained  inside  the  cells 
of asthmatics,  whereas  cell-associated  LXs levels produced 
by  cells  from  controls  were  significantly  higher,  26.4% 
(P <0.045). 
Stimulation of Mixed Platelet/PMN and Platelet Alone Sus- 
pensions by A  23 I87.  These coincubafions were performed 
to compare the results  with  those described previously. As 
Lipoxin Generation  in Polymorphonuclear Cells from Asthmatic Patients Figure 6.  LXs biosynthesized from A 23187-stimuhted PMN. PMN 
were stimulated by A 23187 (5 p-M) for 5 min at 37~  with 15(S)-HETE 
(3 p.M). The LX group corresponded  to inaterial resolved by HPLC anal- 
ysis under the conditions described in Fig. 2 A, and quantified by external 
standard method under the conditions described in the Fig. 3 legend. Re- 
suits presented as nanograms  per 107 cells are expressed as mean +  SEM 
for the number of  subjects in each population. Filled bars, asthmatics (n = 
13); hashed bars, controls (n = 7). LX biosynthesis in PMN from asthmat- 
ics was twofold higher than in PMN from controls with highly significant 
differences. Statistical analysis (Mann-Whitney U  test): LXB  4 isomers, 
P <0.000l;  LXA  4 isomers, P  <0.0005;  LXA  4  P  <0.0001;  6S-LXA4, 
P <0.0005; total LXs, P <0.0001 (Mann-Whitney U test). 
reported in the literature  (32), a platelets/PMN ratio of 100 
was required to produce 52 ng of  LXs when 107 leukocytes 
were incubated with A  23187  (1  ~M)  at 37~  for 30 rain. 
LX levels were produced linearly according to the platelet/ 
PMN ratio, and 107 PMN required fivefold more platelets  to 
produce 28.8 ng of total LXs with only 30 ng of 5(S),15(S)- 
diHETE (data not shown). In the same conditions, platelets 
alone  (5  ￿  107) were  able  to produce  12-HETE  (72  ng) 
and HHT  (70 ng) without any detectable amounts of other 
metabolites. 
Discussion 
We investigated  the generation of di- and trihydroxyei- 
cosatetraenoic  acids  by  A  23187-stimulated  PMN  incu- 
bated in the presence or absence of 15(S)-HETE. We dem- 
onstrated  (a)  that the  total  amounts  of LXs biosynthesized 
by PMN  from asthmatics  were  twofold higher than  those 
biosynthesized  by PMN  from controls;  and  (b)  in  the  ab- 
sence of  exogenous 15(S)-HETE, PMN from asthmatics were 
able to produce 5(S),15(S)-diHETE  and LXs from endoge- 
nous sources, whereas in the same experimental  conditions, 
no detectable  amounts of these compounds appeared in the 
PMN from controls. 
Human blood PMN were isolated and purified to avoid 
any contaminating cells  such  as  erythrocytes and platelets, 
and thus eliminate  any possible  eicosanoid synthesis result- 
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ing from transcellular metabolism. ILP-HPLC coupled with 
a  multi-wave length spectrophotometer detector was use- 
ful in resolving and monitoring products containing conju- 
gated triene and tetraene. Aliquots of samples were directly 
injected into an isocratic RP-HPLC system, and the analy- 
sis procedure  did not involve solid-phase  extraction,  con- 
centration,  or derivatization.  The  samples  only had  to  be 
deproteinized  and  centrifuged,  thus  minimizing  double- 
bond isomerization,  loss,  and deterioration  of eicosanoids. 
Moreover,  for cis-double-bond  isomerization,  the  samples 
had to be left overnight at room temperature,  as previously 
reported  (16).  The  presence  and  identity  of UV  chro- 
mophores were  characterized by their retention  times  and 
spectra in the stop-flow mode. 
The aim of  our study was to demonstrate the PMN hyper- 
activation consecutive to asthma, measuring the cell capacity 
to generate,  via the 5-LO pathway, LXs from endogenous 
arachidonic acid or from exogenously added 15(S)-HETE. 
PMN  from asthmatics  exposed  to  A  23187  (5  gM)  at 
37~  for 5  min  released  higher  levels  of LTs  than  PMN 
from  controls  into  the  culture  medium.  In  contrast  to 
PMN from controls, they were able to synthesize high lev- 
els of 5(S),15(S)-diHETE  and substantial amounts of prod- 
ucts  containing  conjugated  tetraene  chromophore  14S-8- 
trans-LXB 4  and  8-trans-LXB 4,  LXB  4,  6S-11-trans-LXA  4 
and  6tL-11-trans-LXA  4,  LXA 4,  and  6S-LXA  4.  When  ex- 
posed to  15(S)-HETE  (3  ~M), A  23187-stimulated  PMN 
generated  metabolites  from  endogenous  and  exogenous 
sources.  PMN  were  able  to  synthezise  20-OH-LTB4 and 
LTB4  (without  A6-trans-LTB4)  and  to  transform  15(S)- 
HETE into conjugated diene derivative 5(S), 15 (S)-diHETE 
and  into  seven  products  containing  conjugated  tetraene 
chromophore: 14S-8-trans-LXB 4 and 8-trans-LXB 4, 6S-11- 
trans-LXA 4  and  6R-11-trans-LXA  4,  7-cis-l l-trans-LXA 4, 
LXA4,  and  6S-LXA 4.  5(S),15(S)-diHETE  was not the  re- 
sult of 15(S)-HETE autoxidation since they were not avail- 
able in control incubations carried out in a cell-free system 
(data not shown). The presence of all trans-LXs isomers and 
the absence of LXB  4 may not have been the result of dou- 
ble-bond isomerization owing to the extraction procedure, 
since  in  the  same  analysis  conditions,  LXB 4  was  clearly 
generated  by asthmatics  cells.  The  main  important  differ- 
ences in the experiments  carried  out in  this  study are  thus 
summarized  by  the  following  observations  related  to  the 
LXs formation:  (a)  human  PMN  did not generate  natural 
LXB 4  from  exogenous  sources  in  amounts  that  could  be 
detected in our analysis conditions: and (b) only PMN from 
patients with pulmonary disease were able to biosynthesize 
LXs from endogenous sources with high LXB  4 levels,  and 
to  produce  from  exogenous  sources  twofold higher  total 
LX levels than cells from controls. 
The  metabolic  pathway  involved  to  account  for  LXs 
generation by human PMN was reported in Scheme  1.  In 
five experiments,  15-HPETE led to the same reaction prod- 
uct profile as obtained by Kim for rat AM (33, 34)  and by 
Chavis  et  al.  for human  AM  (16).  Hence,  the  metabolic 
pathway previously suggested for human AM may explain 
LX generation by human PMN. As previously reported by A)  ENDOGENOUS  SOURCES  B)  TRANSCELLULAR  METABOLISM 
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Scheme 1.  Hypothetical pathways for LX generation by human neutrophils. (A) Generation of 5(S),15(S)-diHETE and LXs from endogenous arachi- 
donic acid by the involvement of the delocalized  carbocation  intermedicate described by Corey et al. (39) and Serhan (13, 42) as a possible LX precursor 
in the metabohzation of 15(S)-HETE via the formation of human leukocytes. (B) Metabolization of exogenous 15(S)-HETE via the formation of 5,6- 
epoxytetraene, according to Serhan et al. (12), R.okach et al. (38), and to previous results obtained with AM (16). 
Serhan et al.  (30, 35-37), LX biosynthesis occurred via for- 
mation  of the  epox-ytetraene  intermediate  15-OH-LTA4 
generated  from  5-hydroperoxy,15-hydroxyeicosatetraenoic 
acid,  whose  enzymatic  opening  led  to  natural  LXA  4 and 
nonenzymatic opening to all-trans  LX isomers  (38),  as de- 
scribed in Scheme 1 B. 
LX biosynthesis from endogenous sources was explained 
in Scheme  1 A. The 5-HPETE generated in a first step by 
the 5-LO activity led to 5-HETE and LTA  4. Even after cell 
pellet  hydrolysis,  no  detectable  amounts  of 15(S)-HETE 
was recovered, showing that it was not reacylated into cel- 
lular lipid pools or membrane phospholipids.  Although no 
evidence  for  15(S)-HETE  formation  was  shown,  PMN 
from  asthmatics  should  have  displayed  15-LO  activity: 
Nichols et al.  (39) have indicated that the 15-LO in human 
PMN is a cryptic enzyme that needs to be stimulated to me- 
tabolize endogenous substrate.  It is possible that 5-hydroxy- 
eicosanoids,  biosynthezised  by  one  pool  of PMN,  have 
acted as second messengers towards another pool, and that 
they may mimic an as yet unidentified physiological activa- 
tor  of the  15-LO.  15-LO would thus be  able  to generate 
15-OH LTA4 alone. This is similar, however, to the situa- 
tion in the  presence  of exogenous substrate,  where  LXB  4 
levels were too weak to be detected.  15-LO action on the 
small amounts of 5,6-diHETEs occurring from the nonen- 
zymatic LTA4 opening would be  able  to produce  LXs in 
the same manner as platelets  (40), but for the same reason, 
this  mechanism  would  not  be  retained.  Therefore,  since 
15(S)-HETE was not recovered, it was not biosynthesized 
or was rapidly catabolized by to hydroxylation or 13 oxida- 
tion,  being  thus  undetectable  nor  able  to lead  to  LXs.  A 
mechanism involving 5-LO action on the symmetric stable 
horseshoe conformation ascribed by Corey et al. to 5-HPETE 
(41) would thus explain the observed high amounts of LXB  4. 
After rotation of the molecule around its  symmetry axis in 
the enzymatic site consecutive to "special" activation of the 
5-LO, abstraction  of the  hydrogen atom at the  C13 posi- 
tion, identical in this case to the C7 position specific to the 
5-LO  activity  (42),  led  to  5,15-diHPETE.  In a  first  step, 
gluthation peroxidase reduced 5,15-diHPETE to 5(S),15(S)- 
diHETE;  in a  second step,  proton  abstraction  at  the  C10 
position,  specific of the  5-LO  epoxysynthase activity (43), 
generated 5,6- and/or  14,15-epoxytetraenes,  leading to de- 
localized enzyme-bound carbocation as described by Corey 
et al.  (41) and in further works by Serhan (13, 44), explain- 
ing thus LXs formation by water attack from the top "rr face 
of the  complex at  the  C6  or C14 positions.  This  mecha- 
nism pointed to the fact that the in situ endogenous 5(S)- 
HPETE  generation was the key step  for LXA  4 and LXB4 
formation  from  a  common  precursor  in  activated  PMN: 
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from exogenously added 5-HETE, as previously reported 
by Serhan (22). 
This new class of hydroxytetraenes was first isolated and 
characterized by Serhan et al.  (11,  12),  and then described 
using various incubation systems (1, 45). Substantial  amounts 
of LXs were produced by A 23187--stimulated cells accord- 
ing to three different in vitro incubation systems, with or 
without exogenously added substrate. The synthesis of LXs 
generated  by  rat  basophilic  leukemia  cells  (46),  human 
PMN  (22,  30), or AM  (16,  33, 34) incubated with  15(S)- 
HETE,  by  nasal  polyps  (47)  and  permeabilized  human 
platelets  (48)  incubated  with  LTA  4,  and  by granulocytes 
from  eosinophil  donors  incubated  with  arachidonic  acid 
(49),  all  required the  addition  of exogenous substrate.  In 
contrast, the synthesis of LXs generated by human cell-cell 
coincubations such as platelet granulocytes (32), GM-CSF- 
primed  PMN  and  platelets  (21),  or cell-tissue  coincuba- 
tions such as granulocyte nasal polyps (47) did not require 
any exogenous addition since the substrate was provided by 
one cell type and transformed by the other by a transcellu- 
lar metabolism mechanism. The synthesis of LXs generated 
by cells from hematopoietic organs, such as bone marrow 
cells  (50)  or, more recently, macrophage-like cells isolated 
from rainbow  trout  (51,  52),  was  proceeded by one cell 
type without the addition of any exogenous substrate and 
without the participation of surrounding cells. 
This is the first time that the simultaneous generation of 
5(S),15(S)-diHETE and LXs in vitro by human phagocytes 
has been reported without exogenous addition of any pre- 
cursor and without in vitro cytokine priming. These results 
on LX generation from endogenous sources cannot be in- 
terpreted by a dual cell system involving platelet contami- 
nation: in fact, the platelet/PMN ratio required to generate 
the  same  metabolite  level  was  from  50  to  100,  which 
would be far beyond such a ratio because of the remaining 
adherent platelets after the purification process. Our analy- 
sis of experiments with asthmatics' PMN preparations did 
not show the presence ofLTC  4 in contrast to the results re- 
ported by Macloufet al. (53) for mixed platelet/PMN sus- 
pensions. Moreover, when 15(S)-HETE was  added to the 
cells in  the  presence  of MK  886,  a  specific  inhibitor  of 
PMN 5-LO translocation (54), metabolite biosynthesis was 
completely stopped, whereas if PMN suspensions had been 
contaminated, the action of the platelet 12-LO would have 
led to the formation of 8,15-diHETE after hydrogen ab- 
straction  at  C10  on  the  15(S)-HETE  molecule.  Finally, 
high levels of 5(S), 15(S)-diHETE were not obtained when 
PMN were stimulated in the presence of various quantities 
of platelets in the absence of 15(S)-HETE. This suggested 
that LX generation could arise  neither from LX synthase 
activity of  human platelet 12-LO (55) nor by stimulation of 
LX synthesis by endogenously formed 12-HETE in plate- 
lets (56). Therefore, 5(S),15(S)-diHETE and LXs are actu- 
ally generated in vitro by the asthmatics blood PMN from 
their endogenous arachidonate pools. On the other hand, 
PMN  from  asthmatics  metabolized  twofold more  15(S)- 
HETE and produced twofold greater quantities of each LX 
species  than PMN from controls. The higher levels of LXs 
in  asthmatics'  PMN  and  the  metabolic steps  involved in 
LXs formation indicated that in vitro 5(S),15(S)-diHETE 
and  LXs generations  reflected in  vivo-priming of PMN: 
this priming may be induced in bronchial diseases by cy- 
tokines (21) or TNF-oe released by other blood cells or by 
pulmonary cells involving interleukin or TNF-0e/LX axis, 
similar to the TNF-0t/LT axis described in lung endotoxin 
shock (57, 58).  In conclusion, LXs and 5(S),15(S)-diHETE, 
already considered as biomarkers of inflammatory states (18, 
19), may be more specific than LTB  4 in pulmonary diseases. 
The  data  presented  here  demonstrate  that  the  use  of 
15(S)-HETE as an exogenous substrate is a useful approach 
for  assessing  the  PMN  5-LO  activation  status  indepen- 
dently of endogenous arachidonic acid availability. Human 
PMN  were thus  shown  to be  15(S)-HETE metabolizing 
cells,  and  the  relationship  between  LX  formation  and 
15(S)-HETE  substrate  availability  suggested  that  in  vivo 
there may be an interaction between PMN and surround- 
ing inflammatory cells that could serve as 15(S)-HETE do- 
nors.  Since  transcellular  metabolism  is  considered  as  a 
mechanism of eicosanoid biosynthesis (59),  the production 
of LXA  4 identified in whole blood by Serhan  et al.  (20) 
may have  been  the  result  of a  cell-cell cooperation be- 
tween leukocytes and other cells.  The primary sources of 
15(S)-HETE,  depending  on  the  extent  of inflammation, 
are likely eosinophils with active  15-LO activity (28).  In 
bronchial diseases,  however, vascular endothelial cells  are 
now considered to be active inflammatory cells rather than 
a biological barrier to body fluids (60). The priming of hu- 
man PMN, specifically asthmatics cells, might be explained 
by potential cellular interactions with vascular endothelial 
cells  since  several  authors  reported  evidence  of an  LO- 
dependent mechanism in  PMN  adherence to  endothelial 
cells (61-64). It will be of interest to proceed further with 
this work to elucidate whether cell-associated LX amounts 
have any significance, knowing the physiological properties 
of  LXA 4 (13), and to investigate the mechanism of cell-cell 
interactions that could be involved in arachidonic acid me- 
tabolism by human  cells from the hematovascular system, 
and to provide a link between cellular lipid mediators and 
cell-mediated immunity in the context of  pulmonary diseases. 
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